


## Kusunokinin

Cat. No.:	HY-N10798
CAS No.:	58311-20-9
Molecular Formula:	C <sub>21</sub> H <sub>22</sub> O <sub>6</sub>
Molecular Weight:	370.4
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Kusunokinin ((-)-Kusunokinin) is a nature product that could be isolated form <i>P. nigrum</i> . Kusunokinin has anticancer activity. Kusunokinin arrests cell cycle at G2/M phase and induce apoptosis <sup>[1]</sup> .									
<b>In Vitro</b>	<p>Kusunokinin ((-)-Kusunokinin; 0.625-10 µg/mL; 72 h) inhibits the viability of cancer cells with IC<sub>50</sub> values of 3.08, 3.59, 3.98, 5.75, 5.77, 7.86 µM for MCF-7, HT-29, MDA-MB-468, SW-620, A-549, MDA-MB-231 cells, respectively<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Cancer cells</td> </tr> <tr> <td>Concentration:</td> <td>0.625, 1.25, 2.5, 5 and 10 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Had anticancer activity and inhibited cancer cells growth.</td> </tr> </table>		Cell Line:	Cancer cells	Concentration:	0.625, 1.25, 2.5, 5 and 10 µg/mL	Incubation Time:	72 hours	Result:	Had anticancer activity and inhibited cancer cells growth.
Cell Line:	Cancer cells									
Concentration:	0.625, 1.25, 2.5, 5 and 10 µg/mL									
Incubation Time:	72 hours									
Result:	Had anticancer activity and inhibited cancer cells growth.									
<b>In Vivo</b>	<p>Kusunokinin ((-)-Kusunokinin; 7 and 14 mg/kg; i.h.; 3 times a week for 2 weeks) attenuates tumor growth in NMU-induced breast cancer rats through the down-regulation of signaling molecules (c-Src, PI3K, Akt and Erk1/2)<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female Sprague Dawley rats (7 weeks of age)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>7 and 14 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Subcutaneous injection, 3 times a week for 2 weeks</td> </tr> <tr> <td>Result:</td> <td>Inhibited the mammary tumor growth and decreased tumor volume. Down-regulated c-Src, Erk1/2 and PI3K proteins and decreased Akt proteins. Inhibited downstream molecules in the cell cycle (c-Myc, E2f-1, CDK1 and cyclin B1) and metastasis (E-cadherin, MMP-2 and MMP-9).</td> </tr> </table>		Animal Model:	Female Sprague Dawley rats (7 weeks of age) <sup>[1]</sup>	Dosage:	7 and 14 mg/kg	Administration:	Subcutaneous injection, 3 times a week for 2 weeks	Result:	Inhibited the mammary tumor growth and decreased tumor volume. Down-regulated c-Src, Erk1/2 and PI3K proteins and decreased Akt proteins. Inhibited downstream molecules in the cell cycle (c-Myc, E2f-1, CDK1 and cyclin B1) and metastasis (E-cadherin, MMP-2 and MMP-9).
Animal Model:	Female Sprague Dawley rats (7 weeks of age) <sup>[1]</sup>									
Dosage:	7 and 14 mg/kg									
Administration:	Subcutaneous injection, 3 times a week for 2 weeks									
Result:	Inhibited the mammary tumor growth and decreased tumor volume. Down-regulated c-Src, Erk1/2 and PI3K proteins and decreased Akt proteins. Inhibited downstream molecules in the cell cycle (c-Myc, E2f-1, CDK1 and cyclin B1) and metastasis (E-cadherin, MMP-2 and MMP-9).									

### REFERENCES

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA